LL-37

LL-37 is presented here as a laboratory catalogue entry for research environments that need clear identification, labelled variants, and direct access to supporting records. The current listing includes 2 labelled variants: 5mg and 10mg. That structure keeps the page useful as both a procurement reference and an indexable resource covering stock visibility, pricing context, and documentation.

Within the wider Au Peptide Labs catalogue, LL-37 sits alongside Retatrutide, Tesamorelin, and Ipamorelin. Researchers often review neighbouring compounds before selecting a comparator or deciding which sequence belongs in a screening panel. Keeping those internal paths close to the product page improves traceability and helps laboratory buyers compare materials without relying on vague or consumer-style copy.

In research literature, LL-37 is generally treated as a short research peptide reviewed in cell-migration, matrix-signalling, and antimicrobial assay models. BPC-157 is a 15-amino acid pentadecapeptide derived from the partial sequence of human gastric juice protein BPC. In cell-based models it has been studied for interactions with NO/eNOS signalling, VEGFR2-mediated angiogenic pathways, and focal adhesion kinase (FAK)/paxillin complexes relevant to cell-migration assays. TB-500 corresponds to the active fragment of thymosin β4 containing the actin-sequestering LKKTET motif; it binds G-actin with high affinity, reduces the G/F-actin ratio, and modulates cell migration and angiogenesis signalling in scratch-assay models. LL-37 is a 37-residue human cathelicidin antimicrobial peptide (the C-terminal domain of hCAP18) that adopts an amphipathic α-helix at physiological ionic strength; it disrupts bacterial membranes, signals through formyl-peptide receptor-like 1 (FPRL1/FPR2), and modulates innate immune pathway outputs in human cell models.

Research panels combining these peptides often examine matrix remodelling, angiogenic marker expression, or innate immune signalling under well-defined in vitro conditions. Because each peptide operates via distinct molecular targets, selectivity controls and appropriate receptor antagonists are important experimental design considerations. For laboratory teams, the practical emphasis is usually on sequence identity, receptor or pathway relevance where documented, and whether LL-37 behaves consistently across stability, purity, and analytical verification workflows. Variant labels on this page support clearer internal referencing when multiple labelled variants are under review.

If a product-specific file is not attached to this listing, the wider COA library remains the correct reference point for current published documentation. The COA section is useful for confirming how the product is labelled in the catalogue, whether purity information has been published, and whether the laboratory record for the material is complete before bench use.

When teams compare LL-37 with Retatrutide, Tesamorelin, and Ipamorelin, COA access also helps keep comparator decisions grounded in documented material identity rather than assumption. That is especially important for research pages that combine pricing, variant selection, and analytical records on a single URL.